Industry Relations Council
AANN Industry Relations Council (IRC) membership is available to organizations that support the goals and mission of AANN.
The goal of the IRC is to provide a platform to form meaninful relationships and foster dialogue among industry representatives, to gain a greater understanding of mutual areas of interest, and to further programs that benefit patients and their families, neuroscience nurses, and other allied healthcare professionals.
Partnership agreements are renewed anually. The IRC program features tiered participation levels to allow companies of all sizes to enhance their engagement with AANN.
Benefits of IRC participation include
- Annual meeting between company representatives and a select group of AANN Board members and staff to discuss topics of mutual interest
- The ability to survey the AANN Membership
- Opportunity to send a dedicated e-blast to AANN members (sent by AANN on your behalf)
- Registration for the AANN Annual Conference
- Invitation to the President's Reception with AANN Board members
- Year-round recognition on the AANN website, on signage at the Annual Conference, and on the conference website.
To learn more about partnering with AANN, please contact Olivia Diehl at odiehl@aann.org.
Download the IRC Benefits and Application
Industry Relations Council Members
AANN proudly recognizes the following IRC corporate partners and thanks to them for their support. Please note, AANN does not endorse any company or product.
Executive Level
As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we are a fully integrated pharmaceutical business with discovery, clinical, and marketing capabilities. Our key areas of focus include oncology and neurology (dementia-related diseases and neurodegenerative diseases). To learn more about Eisai Inc., please visit us at www.eisai.com/US and follow us on Twitter and LinkedIn.
Learn about patient assistance on Eisai's website
View clinical trial information
At Eisai Inc., human health care (hhc) is our mission and is the shared purpose that connects us to those we serve creating a network of powerful relationships that enables us to identify, understand and work to address the needs of people throughout their lives. We boldly push past the boundaries of science and aim to deliver life-changing therapies and health-related solutions that matter to people and society. We bring together science, technology and real-world expertise to pursue a world free from cancer, Alzheimer's disease and other neurodegenerative diseases.
Everything we do is guided by the simple principle that patients and their families come first, and we have a responsibility to listen to and learn from them.
Eisai Inc. is the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd. The company's presence in the U.S. includes three discovery centers as well as commercial, clinical development and global demand organizations. To learn more about Eisai, please visit us, and follow us on Twitter, and LinkedIn. For more information on our work in neurology, please visit the Eisai U.S. Neurology LinkedIn.
Following Traditional Approval of LEQEMBI® (lecanemab-irmb), Eisai has created new resources to provide information and support to patients and their care partners around diagnosis and treatment. These resources can be found on www.LEQEMBI.com
The Eisai Patient Support Program is also available and offers assistance programs that help people prescribed LEQEMBI and their care partners:
• Understand their insurance coverage
• Identify financial support programs for eligible patients
• Know what to expect each step of the treatment journey
Participants may contact the Eisai Patient Support Program by visiting www.eisaipatientsupport.com/leqembi or by calling 1-833-453-7362, Monday-Friday, 8 AM to 8 PM Eastern Time.
Please click here for full Prescribing Information, including Boxed WARNING.
Lilly was founded in 1876 by Colonel Eli Lilly, a man committed to creating high-quality medicines that met real needs in an era of unreliable elixirs peddled by questionable characters. His charge to the generations of employees who have followed was this: "Take what you find here and make it better and better."
More than 145 years later, we remain committed to his vision through every aspect of our business and the people we serve starting with those who take our medicines, and extending to health care professionals, employees and the communities in which we live.
Neurelis, Inc., is a neuroscience company focused on the development and commercialization of therapeutics for the treatment of epilepsy and orphan disorders characterized by high unmet medical need. For more information on Neurelis, please visit www.neurelis.com.
The Stellina™ Study
The Stellina Study is a Phase 1b/2a clinical study evaluating a single dose of diazepam intranasal spray (VALTOCO®) as a rescue medication in children aged 2-5 who have been diagnosed with epilepsy. The objectives of the study are to assess the pharmacokinetics (PK) of diazepam after one intranasal dose of VALTOCO as well as assessing the long-term safety and tolerability in the six-month open-label extension.
Click here for more information and to enroll.
January 2020 Update:
Neurelis announces the FDA approval of VALTOCO, the first nasal seizure rescue medication for ages 6 and above – read the Press Release for details.
Patient service program, myNEURELIS™ (1-866-696-3873). For more information on VALTOCO, please visit www.valtoco.com
- MIND-TD questionnaire
- How to do an AIMS exam
AIMS scorecard (pg. 15) - Neurocrine Biosciences CPL Team 2023
Servier is a commercial stage, privately held pharmaceutical company. Launched by Servier Group, an organization operating in more than 150 countries and governed by a non-profit foundation, Servier Pharmaceuticals has the resources and network of an established global pharmaceutical company, while operating with the nimble and entrepreneurial spirit of biotech.
At UCB, patients are at the heart of everything we do, inspiring us and driving our scientific discovery. By fulfilling this commitment, more impactful medicines are on the horizon. With a team of approximately 8,300 employees and operations in nearly 40 countries, we are a global biopharmaceutical company investing in cutting-edge scientific research.
Corporate Level
Assertio is a specialty pharmaceutical company offering differentiated products to patients utilizing a non-personal promotional model. We have built and continue to build our commercial portfolio by identifying new opportunities within our existing products as well as acquisitions or licensing of additional approved products. To learn more about Assertio, visit www.assertiotx.com.
Azurity specializes in providing innovative, high-quality medicines that serve overlooked patients. We supply a large number of products to treat a wide range of medical conditions. These include cardiovascular, central nervous system, endocrine, gastro-intestinal, anti-infective and oncology medicines. Many of our medicines are dose-form innovations for patients with needs that are not met by other available products. Our medicines have benefited millions of people.
At Jazz Pharmaceuticals plc, our purpose is to innovate to transform the lives of patients and their families.
We are focused on developing life-changing medicines for people with serious diseases — often with limited or no options — so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again.
We are a fully integrated, global biopharmaceutical company with a diverse portfolio of marketed medicines and novel product candidates for adults and children, and expertise in two key therapeutic areas: neuroscience and oncology. We are an industry leader in treating sleep disorders and epilepsy, and in oncology we are investigating and delivering medicines for hard-to-treat hematologic malignancies and solid tumors. We use our deep knowledge of and commitment to these fields to innovate and identify new solutions where none previously existed.
Marinus Pharmaceuticals, Inc. is developing treatments for seizure disorders. ZTALMY® (ganaxolone) oral suspension, CV is approved for seizures associated with CDKL5 deficiency disorder in patients 2 years of age and older. Ganaxolone is being studied in other seizure disorders, including an investigational IV formulation for refractory status epilepticus.